Table 2.

Randomized, double-blind, placebo-controlled safety and immunogenicity study design among subjects with subclinicalH. pylori infection

No. of subjectsRandomized assignment
VaccineAdjuvant
22.5 × 1010HWCPlacebo-adjuvant
3Placebo-vaccineLTR192G
5Placebo-vaccinePlacebo-adjuvant
82.5 × 1010 HWCLTR192G